Bellevue Group AG Cuts Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Bellevue Group AG decreased its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 26.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 736,390 shares of the pharmaceutical company’s stock after selling 266,345 shares during the period. Vertex Pharmaceuticals […]

Related Keywords

Brucei Sachs ,Reshma Kewalramani ,Piper Sandler ,News Ratings For Vertex Pharmaceuticals Daily ,Insider Transactions At Vertex Pharmaceuticals ,Canaccord Genuity Group ,Securities Exchange Commission ,Vertex Pharmaceuticals Profile ,Wolfe Research ,Bellevue Group ,Telos Capital Management Inc ,Quarter For Vertex Pharmaceuticals ,Investment Management ,Cantor Fitzgerald ,Exchange Commission ,Vertex Pharmaceuticals Incorporated ,Vertex Pharmaceuticals ,Sherbrooke Park Advisers ,Vertex Pharmaceuticals Stock ,Morgan Stanley ,Free Report ,Park Advisers ,Capital Management ,Grey Street Capital ,Street Capital ,Director Bruce ,Pharmaceuticals Incorporated ,Get Free Report ,Vertex Pharmaceuticals Daily ,